Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Emmaus Life Sciences Inc's Business Segments
Emmaus Life Sciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Endari US
Total Revenue
$ 12
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Endari US59.2%
- Product and Service Other0.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 7 | 59.2% |
| Product and Service Other | $ 0 | 0.4% |
Revenue by Product & Service Category - FY
- Endari US82.5%
- Endari International16.8%
- Product and Service Other0.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 2 | 82.5% |
| Endari International | $ 0 | 16.8% |
| Product and Service Other | $ 0 | 0.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Endari US59.2%
- Product and Service Other0.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 7 | 59.2% |
| Product and Service Other | $ 0 | 0.4% |
Description of Emmaus Life Sciences Inc
Emmaus Life Sciences Inc. is a pharmaceutical company that specializes in the research, development, and commercialization of innovative treatments for rare and orphan diseases. The company was founded in 2000 and is headquartered in Torrance, California.
Emmaus Life Sciences is committed to improving the lives of patients suffering from rare and debilitating conditions by developing effective therapies that address the underlying causes of these diseases. Their focus lies in the development of drugs that utilize pre-existing FDA-approved drugs with known safety profiles to treat these conditions.
One of Emmaus' most notable achievements is the development of Endari (L-glutamine oral powder), which has been approved by the FDA to reduce acute complications of sickle cell disease. Endari is a breakthrough treatment that offers significant benefits for patients suffering from this debilitating condition.
The company's research and development efforts are led by a team of highly skilled scientists and researchers who work tirelessly to identify potential therapeutic targets and develop novel treatments. Emmaus collaborates with academic institutions, medical centers, and other industry partners to accelerate the development of its pipeline candidates.
In addition to its commitment to developing new therapies, Emmaus is also dedicated to providing support and education to patients and healthcare professionals. They offer comprehensive resources and materials to assist patients in managing their conditions and improving their quality of life.
Emmaus Life Sciences is deeply committed to meeting the unmet medical needs of patients with rare and orphan diseases. Through their innovative research and development efforts, they aim to transform the lives of patients who have limited treatment options and offer them hope for a better future.
Overall, Emmaus Life Sciences Inc. is a pioneering pharmaceutical company that places a strong emphasis on scientific innovation, patient support, and improving the standard of care for individuals suffering from rare and orphan diseases.
Emmaus Life Sciences is committed to improving the lives of patients suffering from rare and debilitating conditions by developing effective therapies that address the underlying causes of these diseases. Their focus lies in the development of drugs that utilize pre-existing FDA-approved drugs with known safety profiles to treat these conditions.
One of Emmaus' most notable achievements is the development of Endari (L-glutamine oral powder), which has been approved by the FDA to reduce acute complications of sickle cell disease. Endari is a breakthrough treatment that offers significant benefits for patients suffering from this debilitating condition.
The company's research and development efforts are led by a team of highly skilled scientists and researchers who work tirelessly to identify potential therapeutic targets and develop novel treatments. Emmaus collaborates with academic institutions, medical centers, and other industry partners to accelerate the development of its pipeline candidates.
In addition to its commitment to developing new therapies, Emmaus is also dedicated to providing support and education to patients and healthcare professionals. They offer comprehensive resources and materials to assist patients in managing their conditions and improving their quality of life.
Emmaus Life Sciences is deeply committed to meeting the unmet medical needs of patients with rare and orphan diseases. Through their innovative research and development efforts, they aim to transform the lives of patients who have limited treatment options and offer them hope for a better future.
Overall, Emmaus Life Sciences Inc. is a pioneering pharmaceutical company that places a strong emphasis on scientific innovation, patient support, and improving the standard of care for individuals suffering from rare and orphan diseases.
Emmaus Life Sciences Inc. is a biotechnology company primarily focused on developing and commercializing innovative therapeutic products for the treatment of rare and chronic diseases. The company is known for its commitment to addressing unmet medical needs through its research and development initiatives. Below, Ive outlined the key segments, products, and services offered by Emmaus Life Sciences.
Segments
1. Rare Diseases: Emmaus Life Sciences specializes in developing treatments for rare genetic and metabolic disorders. Their focus is on diseases that may not have adequate treatment options available, thereby improving the quality of life for affected individuals.
2. Chronic Conditions: The companys research extends to chronic conditions that require long-term management and where novel therapeutic solutions could significantly alter patient care.
3. Research and Development: Emmaus invests significantly in R&D to discover, develop, and commercialize effective therapeutics. This segment encompasses preclinical studies, clinical trials, and collaborations with academic institutions and other research entities.
Products
1. Endari (L-Glutamine) Powder:
- Indication: Endari is a prescription dietary supplement that is primarily used as a treatment for patients with sickle cell disease (SCD). This condition is characterized by the presence of abnormal hemoglobin, leading to anemia and painful episodes.
- Mechanism: The L-glutamine compound in Endari works by reducing the frequency of sickle cell crises and improving overall health-related quality of life.
- Administration: It is available in a powdered form and is mixed with liquids or soft foods, making it accessible for patients.
2. Other Pipeline Products: Emmaus is involved in the development of other therapeutic products addressing additional rare diseases and unmet needs. These products are typically in various stages of development, from preclinical to late-stage clinical trials.
Services
1. Clinical Trials Management: Emmaus Life Sciences conducts and manages clinical trials to evaluate the safety and efficacy of its products. This includes designing the trial protocols, patient recruitment, data collection, and analysis.
2. Regulatory Affairs: The company has a dedicated team that navigates the complex regulatory landscape to gain approvals from authorities such as the FDA (Food and Drug Administration). This service ensures compliance with all regulatory requirements for drug approval and maintenance.
3. Patient Support Programs: Emmaus recognizes the importance of patient education and support. They offer programs that facilitate adherence to treatment regimens, provide information about their therapies, and address the concerns of patients and caregivers.
4. Collaboration and Partnerships: Emmaus pursues strategic collaborations with other biotech companies, research institutions, and healthcare providers to enhance its research initiatives and market reach. These partnerships can offer innovative approaches in treatment development and distribution.
5. Healthcare Provider Engagement: The company actively engages healthcare professionals to ensure that they are informed about its products and their clinical applications. This may include educational programs, resources, and the provision of scientific data to support practitioners in their treatment decision-making.
Conclusion
Emmaus Life Sciences Inc. is firmly committed to providing solutions for patients struggling with rare and chronic diseases. Through its innovative products, robust R&D initiatives, and comprehensive services, the company aims to improve patient outcomes and enhance the overall landscape of therapeutic options available in the market.
Segments
1. Rare Diseases: Emmaus Life Sciences specializes in developing treatments for rare genetic and metabolic disorders. Their focus is on diseases that may not have adequate treatment options available, thereby improving the quality of life for affected individuals.
2. Chronic Conditions: The companys research extends to chronic conditions that require long-term management and where novel therapeutic solutions could significantly alter patient care.
3. Research and Development: Emmaus invests significantly in R&D to discover, develop, and commercialize effective therapeutics. This segment encompasses preclinical studies, clinical trials, and collaborations with academic institutions and other research entities.
Products
1. Endari (L-Glutamine) Powder:
- Indication: Endari is a prescription dietary supplement that is primarily used as a treatment for patients with sickle cell disease (SCD). This condition is characterized by the presence of abnormal hemoglobin, leading to anemia and painful episodes.
- Mechanism: The L-glutamine compound in Endari works by reducing the frequency of sickle cell crises and improving overall health-related quality of life.
- Administration: It is available in a powdered form and is mixed with liquids or soft foods, making it accessible for patients.
2. Other Pipeline Products: Emmaus is involved in the development of other therapeutic products addressing additional rare diseases and unmet needs. These products are typically in various stages of development, from preclinical to late-stage clinical trials.
Services
1. Clinical Trials Management: Emmaus Life Sciences conducts and manages clinical trials to evaluate the safety and efficacy of its products. This includes designing the trial protocols, patient recruitment, data collection, and analysis.
2. Regulatory Affairs: The company has a dedicated team that navigates the complex regulatory landscape to gain approvals from authorities such as the FDA (Food and Drug Administration). This service ensures compliance with all regulatory requirements for drug approval and maintenance.
3. Patient Support Programs: Emmaus recognizes the importance of patient education and support. They offer programs that facilitate adherence to treatment regimens, provide information about their therapies, and address the concerns of patients and caregivers.
4. Collaboration and Partnerships: Emmaus pursues strategic collaborations with other biotech companies, research institutions, and healthcare providers to enhance its research initiatives and market reach. These partnerships can offer innovative approaches in treatment development and distribution.
5. Healthcare Provider Engagement: The company actively engages healthcare professionals to ensure that they are informed about its products and their clinical applications. This may include educational programs, resources, and the provision of scientific data to support practitioners in their treatment decision-making.
Conclusion
Emmaus Life Sciences Inc. is firmly committed to providing solutions for patients struggling with rare and chronic diseases. Through its innovative products, robust R&D initiatives, and comprehensive services, the company aims to improve patient outcomes and enhance the overall landscape of therapeutic options available in the market.